Page 126 · Drug diffusion across the stratum corneum — the lipid-mortar barrier of the skin — and how chemical penetration enhancers unlock greater flux
Every transdermal patch must first defeat the stratum corneum (SC) — a thin, dead, and deceptively formidable outer layer of the epidermis. Composed of 10–20 layers of flattened, anucleate corneocytes embedded in a continuous, highly ordered lipid matrix, the SC is only 10–20 µm thick yet accounts for the overwhelming majority of skin's resistance to molecular transport. Understanding its architecture is the starting point for any rational transdermal drug delivery design.
The classic "brick and mortar" model, first proposed by Michaels et al. (1975) and refined by Elias's work on epidermal lipids, describes the stratum corneum as:
• Bricks — corneocytes: terminally differentiated keratinocytes that have lost their nuclei and organelles, flattened into hexagonal plates roughly 30–40 µm wide and 0.2–0.5 µm thick, densely packed with cross-linked keratin filaments and surrounded by a cornified envelope of structural proteins (involucrin, loricrin).
• Mortar — intercellular lipid matrix: a continuous, multilamellar sheet of ceramides (~50% by mass), free fatty acids (~15%), and cholesterol (~25%) organized into stacked bilayers that fill every gap between corneocytes with no aqueous shortcut.
Critically, corneocytes are essentially impermeable to most drug molecules — their interior is a dense keratin gel. This forces nearly all diffusive transport into the lipid mortar phase, making lipid organization the single most important determinant of transdermal permeability.
Because the mortar is continuous and the bricks are not, the stratum corneum behaves less like a wall and more like a maze — permeation is possible, but only along a narrow, lipid-lined corridor that winds around every corneocyte in its path.
Beneath the stratum corneum lie the viable epidermis and dermis — living, well-hydrated, vascularized tissue that offers comparatively little resistance to most small-to-moderate molecules once they clear the SC. The dermis is richly perfused with capillaries beginning just below the dermal-epidermal junction, meaning that once a drug reaches viable tissue it is rapidly taken up into systemic circulation.
Consequently, transdermal pharmacokinetics is almost entirely governed by SC transport: the permeability coefficient (Kp) of the intact stratum corneum is typically 100–1,000-fold lower than that of the underlying viable tissue. Formulators therefore focus overwhelmingly on SC-crossing strategies — enhancer chemistry, prodrug design, and physical disruption methods — because gains made there translate almost linearly into overall delivery improvements.
A transdermal patch cannot simply "push" drug through skin; it can only supply a concentration gradient and, optionally, chemical or physical assistance. Patch engineers therefore characterize a candidate molecule's SC-crossing behavior early: molecular weight (ideally <500 Da), melting point (lower is generally better for SC solubility), and log P (optimal window roughly 1–3) are used as first-pass screens before a molecule is even considered patch-compatible.
Because corneocytes block the direct path, drug molecules diffusing passively through intact skin must snake around every brick they encounter, following the continuous lipid channels that wrap each corneocyte. This tortuous intercellular pathway — rather than any transcellular shortcut — is the dominant route for the vast majority of topically applied drugs.
Three theoretical pathways exist across the stratum corneum, but their contributions differ enormously:
• Intercellular (lipid) route: the dominant pathway for the great majority of drugs. Molecules dissolve into and diffuse through the continuous lipid bilayers that wind between corneocytes — a tortuous, tunnel-like path.
• Transcellular route: a theoretical straight-line path directly through corneocytes and the thin lipid layers between them. In practice it requires repeatedly partitioning between a hydrophilic keratin phase and a lipophilic bilayer phase, which is energetically costly — this route is minor for almost all drugs.
• Appendageal (shunt) route: diffusion via hair follicles and sweat glands, which occupy only ~0.1% of skin surface area. Normally negligible for steady-state flux, but can matter for the earliest minutes of large-molecule or nanoparticle delivery, and is deliberately exploited by microneedle and follicular-targeting formulations.
Because corneocytes overlap in a staggered, brick-like arrangement, a molecule cannot travel in a straight line from the skin surface to the viable epidermis. Instead it must repeatedly detour laterally around each corneocyte before it can continue its net downward progress.
Morphometric studies estimate the effective path length a molecule travels through the lipid matrix is 20- to 50-times greater than the physical SC thickness. This tortuosity factor appears directly in Fick's first law as an effective diffusion path length, and it is one of the two dominant reasons (the other being the lipid partition coefficient) that the SC is such an effective barrier despite being only microns thick.
Fick's first law for steady-state flux across the SC: J = (Kp × ΔC), where the permeability coefficient Kp itself bundles together the partition coefficient into the lipid phase, the diffusion coefficient within that phase, and the tortuous path length — Kp = (D × K) / h_eff.
The intercellular lipids are not a disordered fluid but a highly organized, repeating lamellar structure: alternating stacks of crystalline and liquid-crystalline lipid bilayers, stabilized by the unusually long and saturated ceramide acyl chains. Two coexisting lamellar phases have been identified by X-ray diffraction — a short periodicity phase (~6 nm repeat) and a long periodicity phase (~13 nm repeat) — that together form a dense, low-fluidity barrier optimized by evolution to minimize transepidermal water loss. This same tight packing that keeps water in is what keeps most drug molecules out, which is precisely why penetration enhancers target this lamellar order.
Not all molecules cross the stratum corneum equally. Three physicochemical properties dominate the rate of passive permeation: molecular size (which sets the diffusion coefficient), lipophilicity (which sets partitioning into the lipid mortar), and the concentration gradient maintained by the patch reservoir. Small, moderately lipophilic drugs are the classic "good" transdermal candidates.
Diffusion coefficient D within the lipid matrix falls off steeply with increasing molecular volume — larger molecules simply cannot squeeze through the narrow, ordered spacing between lipid bilayers as readily as small ones. Empirical SC permeability models (e.g. Potts & Guy, 1992) express log Kp as a linear combination of log P and molecular weight, consistently showing a negative weight on molecular size. This is why essentially all commercially successful passive transdermal patches deliver small molecules — nicotine (162 Da), fentanyl (336 Da), nitroglycerin (227 Da), scopolamine (303 Da), estradiol (272 Da) — while peptides, proteins, and most biologics require active enhancement technologies (microneedles, iontophoresis) rather than passive patches.
Log P (the octanol-water partition coefficient) predicts how readily a molecule partitions from the patch formulation into the lipid mortar of the SC. But permeation is not simply "more lipophilic is better":
• Too hydrophilic (log P < 0): the molecule struggles to partition out of the aqueous/polar formulation phase and into the lipid bilayers at all — poor entry into the barrier.
• Optimal range (log P ≈ 1–3): the molecule partitions efficiently into the lipid matrix and also diffuses out the far side into the aqueous viable epidermis — good entry AND good exit.
• Too lipophilic (log P > 4–5): the molecule partitions strongly into the SC lipids but then becomes reluctant to leave them for the aqueous viable epidermis, effectively forming a slow-release depot within the skin itself — high SC uptake but poor net flux.
This inverted-U relationship between log P and flux is one of the most robust findings in dermal pharmacokinetics and drives early candidate-selection screens in patch formulation programs.
The Potts-Guy equation, one of the most cited empirical models in transdermal science: log Kp = 0.71·log P − 0.0061·MW − 6.3, fit to over 90 compounds — it captures both the positive contribution of lipophilicity and the negative contribution of molecular size in a single predictive line.
Fick's first law makes flux directly proportional to the concentration difference across the membrane: J = Kp × (C_donor − C_receptor). Because the patch reservoir sits at a much higher concentration than the near-zero concentration in blood, a steep and sustained gradient is maintained for as long as the reservoir remains undepleted and undersaturated. Patch formulators deliberately load drug at or near its saturation solubility in the reservoir matrix to maximize the thermodynamic activity — and therefore the driving force for diffusion — without allowing crystallization, which would remove drug from the diffusible fraction.
When a candidate molecule's intrinsic permeability is too low for a viable patch dose, formulators turn to chemical penetration enhancers (CPEs) — small molecules co-formulated into the patch that reversibly disturb the tightly ordered stratum corneum lipid lamellae, increasing fluidity, disorder, and free volume, and thereby increasing drug diffusivity and partitioning through the barrier.
Most clinically used chemical penetration enhancers act through one or more of these mechanisms:
• Lipid fluidization: the enhancer inserts itself between the ordered ceramide/cholesterol/fatty-acid chains, disrupting the tight packing of the crystalline and liquid-crystalline lamellar phases and lowering the phase-transition temperature — converting rigid gel-phase lipid regions into a more fluid, liquid-crystalline state that molecules can traverse more easily.
• Lipid extraction: some enhancers (notably ethanol and other solvents) partially extract intercellular lipids from the SC, opening additional diffusional micro-channels and directly thinning the effective barrier.
• Protein interaction: certain surfactants and sulfoxides (e.g. DMSO) interact with corneocyte keratin, causing swelling that indirectly loosens the packed brick-and-mortar architecture.
• Co-solvency / drug thermodynamic activity boost: some enhancers act less on the skin and more on the formulation, increasing the drug's effective thermodynamic activity (and hence its driving force to leave the reservoir), independent of any direct skin effect.
Azone (1-dodecylazacycloheptan-2-one), one of the first purpose-designed penetration enhancers (Nelson Research, 1980s), inserts its long alkyl tail among the ceramide chains while its polar head group perturbs the packing at the lipid headgroup region — a molecular "wedge" that can increase flux of some drugs 5- to 10-fold at just 1–5% w/w.
• Alcohols & glycols: ethanol, propylene glycol — solvent action, lipid extraction, and increased drug solubility; ethanol is present in many FDA-approved patches (e.g. some fentanyl, estradiol formulations).
• Fatty acids: oleic acid, linoleic acid — insert into lipid bilayers, creating localized fluid "pools" or defects due to their cis-double-bond kinked geometry, which disrupts tight lamellar packing especially effectively.
• Terpenes: limonene, menthol, eucalyptol — generally regarded as safer/gentler enhancers; disrupt lipid packing with lower irritation potential, increasingly favored in newer formulations.
• Sulfoxides: DMSO — powerful, well-studied enhancer effective at high concentration but associated with skin irritation and odor, limiting its use in modern marketed patches.
• Surfactants: sodium lauryl sulfate and related — effective but often too irritating for chronic wear-time patches; more common in short-contact formulations.
• Azone and analogues: purpose-built, effective at low concentration, active ingredient in several enhancer-containing prescription patches.
Enhancer selection is a careful balancing act. A highly effective enhancer that produces large, uncontrolled increases in flux risks dose-dumping (delivering too much drug too fast) and skin irritation or sensitization from prolonged multi-day wear. Regulatory approval of any enhancer-containing patch therefore requires demonstrating that:
1. Flux enhancement is reproducible and predictable across the labeled wear period 2. The barrier disruption is fully reversible after patch removal, with SC lipid organization returning to baseline 3. Local tolerability (erythema, edema, sensitization) is acceptable for the intended wear duration 4. Enhancer and drug co-permeate at consistent, validated ratios across manufacturing lots
This is why the list of enhancers actually used in approved transdermal products remains relatively short and conservative compared to the very large academic literature on candidate enhancer chemistries.
The defining engineering target of a transdermal patch is steady-state flux: the point at which the rate of drug release from the patch reservoir into the skin equals the rate of drug absorption from the skin into systemic circulation. Reaching and holding this equilibrium — quickly, predictably, and for the intended wear duration — is what separates a therapeutically useful patch from an inconsistent one.
When a patch is first applied, drug must first diffuse into and partition through the stratum corneum before any appears in blood — this produces an initial lag phase with sub-therapeutic plasma levels. As the SC lipid matrix becomes loaded with drug (approaching its own local steady-state concentration profile), the outflow rate into viable tissue rises until it matches the constant inflow rate supplied by the reservoir — flux becomes constant, plasma concentration plateaus, and steady-state delivery is achieved.
Mathematically, for a well-designed system operating below the SC's maximum flux capacity, the observed flux approaches: J_ss = Kp × C_reservoir, and the time to reach ~95% of steady-state flux scales with the square of the effective diffusional path length divided by the diffusion coefficient — which is exactly why the earlier stages (barrier thickness, tortuosity, lipid diffusivity, and any enhancer-driven fluidization) all directly determine how quickly a given patch reaches therapeutic plasma levels.
Because lag time and steady-state flux both depend on the same underlying SC transport parameters, penetration enhancers that raise flux typically also shorten the lag time to steady state — a favorable coupling that improves both the speed and magnitude of transdermal delivery simultaneously.
Transdermal patches are built around one of two rate-control philosophies:
• Membrane-controlled (reservoir) systems: drug is held in a liquid or gel reservoir separated from the skin by a rate-controlling polymeric membrane. The membrane's permeability is engineered to be the true bottleneck, releasing drug at a constant rate largely independent of skin variability — historically used in early nitroglycerin and some fentanyl patches, though less common today due to dose-dumping risk if the membrane is compromised.
• Drug-in-adhesive (matrix) systems: drug is dissolved or dispersed directly in the adhesive polymer layer that contacts the skin; the skin itself becomes the primary rate-controlling barrier. These are thinner, simpler to manufacture, and dominate current marketed products, but require the drug's intrinsic SC permeability (and any co-formulated enhancer) to be well characterized and reproducible, since there is no membrane backstop against variable skin permeability.
Reservoir loading must exceed the total amount expected to permeate over the labeled wear time, with margin for excipient losses and manufacturing variance — but not so much excess that a damaged or heat-exposed patch could dose-dump dangerously. Design considerations converge here:
• Total dose = target flux × skin contact area × wear duration, back-calculated to size the reservoir • Enhancer loading tuned to hit the target Kp without exceeding irritation thresholds validated in dermal safety studies • Adhesive matrix chemistry chosen for compatibility with both drug and enhancer, avoiding crystallization or enhancer volatilization over the wear period • Occlusion effects from the patch backing itself (increased local hydration, mild temperature rise) are factored in, since even the physical presence of a patch modestly increases SC permeability compared to unoccluded skin
The result, when done well, is a patch that reaches steady, near-zero-order drug delivery within hours and sustains it — smoothing out the peaks and troughs typical of oral dosing and enabling multi-day therapy from a single application.